Semaglutide Demonstrated Superior Improvements In Glycaemic Control Vs Placebo In Adults With Type 2 Diabetes

PR63964

BOSTON, Apr. 3 /PRNewswire=KYODO JBN/--

    For non-US medical media only.

    For journalistic assessment and preparation before publication.

    Abstract #OR15-1

    Findings from the first phase 3a clinical trial for semaglutide, an

investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that

treatment with semaglutide administered once-weekly, significantly improved

glycaemic control compared to placebo in adults with type 2 diabetes previously

managed with diet and exercise alone. Results from the SUSTAIN 1 trial were

presented today at the Endocrine Society's 98th Annual Meeting and Expo (ENDO

2016) in Boston, MA, US.[1]

    The 30-week SUSTAIN 1 trial, evaluating the efficacy and safety of

semaglutide monotherapy vs placebo in 388 adults with type 2 diabetes,[1]

showed that, from a mean baseline HbA1c of 8.1%, adults treated with 0.5 mg and

1.0 mg semaglutide achieved significantly greater HbA1c reductions of 1.5% and

1.6%, respectively, vs ＜0.1% with placebo.

    In addition, more adults treated with 0.5 mg and 1.0 mg semaglutide

achieved HbA1c targets compared with placebo: HbA1c ＜7% (74% and 72% vs 25%)

and less than or equal to6.5% (59% and 60% vs 13%). The trial also demonstrated

that adults treated with 0.5 mg and 1.0 mg semaglutide achieved significantly

greater reductions from baseline in mean body weight of 3.7 kg/8.16 lb and 4.5

kg/9.92 lb, respectively, vs 1.0 kg/2.20 lb with placebo.[1]

    "Achieving glycaemic control remains a significant challenge for people

with type 2 diabetes and their treating physicians," said Christopher Sorli,

SUSTAIN 1 investigator and Chair of the Department of Diabetes, Endocrinology

and Metabolism, Billings Clinic, US. "It is encouraging that almost three out

of four adults treated with semaglutide in the SUSTAIN 1 trial achieved the

HbA1c target of less than seven percent."

    Furthermore, adults treated with both doses of semaglutide demonstrated

significantly greater reductions from baseline in fasting plasma glucose

compared with placebo (2.5 mmol/L or 45.2 mg/dL and 2.3 mmol/L or 42.1 mg/dL,

respectively, vs 0.6 mmol/L or 9.9 mg/dL).[1]

    The most common adverse events observed for adults treated with 0.5 mg and

1.0 mg semaglutide and placebo were gastrointestinal, which were mainly mild or

moderate (nausea: 20.3% and 23.8% vs 7.8%; vomiting: 3.9% and 6.9% vs 1.6%;

diarrhoea: 12.5% and 10.8% vs 2.3%). The rate of nausea diminished over time.

Comparable rates of severe adverse events were observed for adults treated with

0.5 mg and 1.0 mg semaglutide compared with placebo (5.5% and 5.4% vs 3.9%).

The proportion of adults discontinuing due to adverse events was low across

treatment groups (6.3% and 5.4% vs 2.3%).[1]

    About semaglutide

    Semaglutide is an analogue of native human glucagon-like peptide-1 (GLP-1)

that stimulates insulin and suppresses glucagon secretion in a

glucose-dependent manner, as well as decreases appetite and food intake.[2]

Semaglutide administered subcutaneously once-weekly is in phase 3 development

for the treatment of type 2 diabetes.

    About SUSTAIN 1

    SUSTAIN 1 is a randomised, double-blind, placebo-controlled, multicentre,

multinational 30-week trial investigating the safety and efficacy of

semaglutide, administered once-weekly, versus placebo in 388 people with type 2

diabetes who had not received any blood glucose lowering therapies 90 days

prior to trial participation. The trial was conducted in Canada, Italy, Japan,

Mexico, Russia, South Africa, UK and the US.

    About the SUSTAIN clinical programme

    SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2

Diabetes) is a clinical programme for semaglutide, administered once-weekly,

that comprises six phase 3a global clinical trials encompassing more than 7,000

people with type 2 diabetes as well as two Japanese trials encompassing around

1,000 people with type 2 diabetes.

    About Novo Nordisk

    Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat other

serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in

75 countries and markets its products in more than 180 countries. For more

information, visit:

novonordisk.com [http://www.novonordisk.com ],

Facebook [http://www.facebook.com/novonordisk ],

Twitter [http://www.twitter.com/novonordisk ],

LinkedIn [http://www.linkedin.com/company/novo-nordisk ],

YouTube [http://www.youtube.com/novonordisk ]

    Further information

    Media:

    Katrine Sperling

    +45-4442-6718

    krsp@novonordisk.com;

    Asa Josefsson

    +45-3079-7708

    aajf@novonordisk.com

    Investors:

    Peter Hugreffe Ankersen

    +45-3075-9085

    phak@novonordisk.com;

    Daniel Bohsen

    +45-3079-6376

    dabo@novonordisk.com;

    Melanie Raouzeos

    +45-3075-3479

    mrz@novonordisk.com;

    Kasper Veje

    +45-3079-8519

    kpvj@novonordisk.com

    References

    1) Sorli C, Harashima S, Tsoukas G, et al. SUSTAIN 1: efficacy and safety

of once-weekly semaglutide monotherapy versus placebo in subjects with type 2

diabetes. Abstract number OR15-1. Endocrine Society's 98th Annual Meeting and

Expo (ENDO 2016), Boston, MA, US; 1-4 April 2016.

    2) Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding

study of the novel once-weekly human GLP-1 analog, semaglutide, compared with

placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes

Care. 2015; 39:231-241.

   SOURCE: Novo Nordisk